Shares of Zogenix Inc. (NASDAQ:ZGNX) traded up 3.3% during trading on Thursday . The company traded as high as $9.27 and last traded at $9.17, with a volume of 65,423 shares trading hands. The stock had previously closed at $8.88.

A number of analysts have recently commented on the company. Brean Capital reissued a “buy” rating and set a $28.00 price target on shares of Zogenix in a research note on Wednesday, May 11th. Zacks Investment Research raised Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, August 13th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $22.75.

The stock has a 50-day moving average price of $9.15 and a 200 day moving average price of $9.57. The company’s market capitalization is $230.30 million.

Zogenix (NASDAQ:ZGNX) last announced its earnings results on Tuesday, August 9th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.05. During the same quarter in the prior year, the company earned ($3.78) earnings per share. The business earned $2.10 million during the quarter, compared to the consensus estimate of $5.36 million. Zogenix’s revenue was down 71.6% compared to the same quarter last year. Analysts predict that Zogenix Inc. will post ($3.24) EPS for the current fiscal year.

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.